Clinical trials: Metastatic Pancreatic Carcinoma
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic…
- Trial name
- NCT06538207
- Testing
- ONO-4578, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Neoplasm, Stomach, Gastric Neoplasms Malignant
Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
This is a phase Ib/II clinical study that has two phases. In phase Ib, the safety evaluation of the extract of Petiveria alliacea (Esperanza) will be carried out in patients with metastatic gastrointestinal tumors (colon…
- Conditions
- Neoplasm, Stomach, Gastric Neoplasms Malignant, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- PA001 (NCT05587088)
- Testing
- Petiveria Alliacea Preparation
- Where
- Colombia
- Volunteers
- 82 people
- Sponsor
- Hospital Universitario San Ignacio
Pancreatic Cancer
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
- Trial name
- NCT00040183
- Testing
- Tarceva (erlotinib HCl, OSI-774)
- Where
- 140 sites in United States, Argentina and 15 more
- Volunteers
- 569 people
- Sponsor
- OSI Pharmaceuticals
Pancreatic Cancer Metastatic
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study is an Ib/II phase clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a second-line treatment for unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07342725
- Testing
- IBI363 + chemotherapy
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer.
- Trial name
- NCT01214720
- Testing
- bevacizumab [Avastin]
- Where
- 101 sites in Australia, Austria and 19 more
- Volunteers
- 607 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
RATIONALE: Collecting and storing samples of blood from patients with cancer and healthy participants to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898482
- Testing
- This is a non-intervention study for all groups., study of socioeconomic and demographic variables
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line…
- Trial name
- CARRIE (NCT02399137)
- Testing
- MM-141, Gemcitabine, Nab-Paclitaxel
- Where
- 66 sites in United States, Canada and 4 more
- Volunteers
- 88 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Cancer Pancreas
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the…
- Trial name
- NCT02109445
- Testing
- PF-03084014, Gemcitabine, Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
Many patients with advanced pancreatic cancer and colorectal cancer experience burdensome and difficult-to-treat symptoms. The impact of multiple symptoms (called "symptom burden") can negatively affect a patient's quality of…
- Conditions
- Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
- Trial name
- CanPan-C (NCT06605430)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- HealthPartners Institute
Pancreatic Adenocarcinoma
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer.
- Trial name
- NCT00593008
- Testing
- Temsirolimus, Gemcitabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
The purpose of this study is to investigate the effect of very low dose decitabine combinate with gemcitabine in the first-line treatment of locally advanced, unresectable and metastatic pancreatic cancer.
- Trial name
- SLOWDOSE001 (NCT02685228)
- Testing
- Decitabine, Gemcitabine
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
- Trial name
- NCT05630183
- Testing
- Botensilimab, Gemcitabine, Nab-paclitaxel
- Where
- 36 sites in United States
- Volunteers
- 81 people
- Sponsor
- Agenus Inc.
Pancreas Cancer, Metastatic, Pancreas Carcinoma
The STRONG Nutrition Support Study for People With Pancreatic Cancer
This single-center pilot randomized controlled trial evaluates the feasibility, acceptability, and preliminary effects of STRONG, a digital nutrition support app delivered alongside remote dietitian-led nutrition counseling, in…
- Trial name
- STRONG (NCT07826780)
- Testing
- STRONG intervention App, individualized remote dietitian
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to…
- Conditions
- KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT03608631
- Testing
- Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Cancer
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients…
- Trial name
- NCT06532331
- Testing
- ONO-7475, ONO-4538, Nab-paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 87 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Cancer
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with…
- Trial name
- NCT00099294
- Testing
- Glufosfamide
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Threshold Pharmaceuticals
Pancreatic Cancer
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer.
- Trial name
- NCT00652366
- Testing
- Erlotinib, escalating dose, Erlotinib, standard dose, Gemcitabine
- Where
- 89 sites in Argentina, Australia and 21 more
- Volunteers
- 467 people
- Sponsor
- Hoffmann-La Roche
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.